

The Moment that *KRAS* Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer

Toshikazu Ushijima¹ and Takayuki Yoshino²

See related article by Benvenuti et al., *Cancer Res* 2007;67:2643–8.

Almost a decade ago, *Cancer Research* published a translational article by Benvenuti and colleagues (1). It was straightforward with three major pieces of data: (i) among 48 metastatic colorectal cancer (mCRC) patients treated with anti-EGFR antibody, cetuximab or panitumumab, those with *KRAS* or *BRAF* mutations had a shorter time to progression; (ii) a colorectal cancer cell line transfected with mutant *KRAS* acquired resistance to cetuximab; and (iii) two colorectal cancer cell lines with *KRAS* mutation showed increased sensitivity to a combination of cetuximab and a MAPK/ERK inhibitor, PD98059.

The study thus confirmed that activating *KRAS* mutations (codons 12 and 13) impaired the response of mCRC to cetuximab and revealed that the activating *BRAF* mutation (V600E) may also be predictive and that inhibition of the MEK–ERK signaling cascade may improve anti-EGFR treatment in cancer cells with activating *KRAS* (and potentially *BRAF*) mutations. The study led to the advancement of multiple fields, as evidenced by its large number of citations (513 times as of October 10, 2016).

Development of *KRAS* Mutations into a Predictive Marker in Practice

The resistance of mCRCs with activating *KRAS* mutation (codons 12 and 13) to cetuximab was initially reported by Lieve and colleagues, also in *Cancer Research* (2), and its impact has been already commented on in this 75th anniversary series (3). The two reports in *Cancer Research* led to two large-scale studies of advanced colorectal cancer specimens collected in randomized control trials by Karapetis and colleagues and by Amado and colleagues (4, 5).

Both studies convincingly showed that patients with *KRAS* mutations in codons 12 and 13 do not benefit from anti-EGFR mAb therapy, namely cetuximab and panitumumab, with HRs of 0.99 for progression-free survival. Patients with wild-type *KRAS* in codons 12 and 13 showed greatly reduced risk with HR of 0.40 and 0.45. The European Medicines Agency and the Food Drug Administration were swift to

bring the request of *KRAS* mutation analysis into the labels of cetuximab and panitumumab in 2008 and 2009, respectively (3, 6).

Knowledge from Basic Science in the Clinical Spotlight

Basic scientists had known from around 1980 that *KRAS* can be activated not only by mutations in codons 12 and 13, but also by those in codon 61 (7). All the mutant proteins showed impaired activity of GTP hydrolysis and resulted in constitutive activation of RAS-mediated signal. Further structural analysis revealed that Gly12 and Gln61 are located at the RAS–GAP binding interface, and their mutations therefore reduced the GTP hydrolysis. Basic scientists had also known the alternative roles of three *RAS* genes, *KRAS*, *HRAS*, and *NRAS*, for decades (7).

These pieces of knowledge in basic science were translated into clinically important information, namely that *KRAS* mutations at codon 61 also conferred resistance to cetuximab in mCRC patients (8). Also, mCRC patients with *NRAS* mutations had no benefit from anti-EGFR therapy (9, 10).

As *RAS* mutations constitutively activate GTPase and induce transformation and cell proliferation, it is reasonably expected that even treatment-naïve mCRC patients with activating *KRAS* mutations will not benefit from anti-EGFR therapy. Two large-scale clinical studies, PRIME and CRYSTAL trials, were conducted to incorporate anti-EGFR mAbs into the first-line doublet chemotherapy of mCRC patients (10, 11). As expected, anti-EGFR therapy showed clear survival benefit for patients with wild-type *KRAS* and *NRAS*. On the other hand, anti-EGFR therapy brought either worse or no benefit on overall survival [HR = 1.25; 95% confidence interval (CI), 1.02–1.55 for PRIME; HR = 1.05; 95% CI, 0.86–1.28 for CRYSTAL] for patients with mutant *KRAS* or *NRAS*. Now, cetuximab and panitumumab are indicated only for patients with wild-type *RAS* (12).

Multiple Players in One Signaling Pathway

Constitutive activation of the RAS–RAF–MEK–MAPK/ERK pathway (ERK signaling) has been known to be critically involved in *RAS*-mutated cancers (13). It was therefore reasonable that Benvenuti and colleagues pointed out the importance of *BRAF* mutation, in addition to *KRAS* mutations, in the resistance to anti-EGFR therapy. Soon, Di Nicolantonio and colleagues showed that none of 11 *KRAS* wild-type and *BRAF*-mutated mCRC patients responded to cetuximab or panitumumab, whereas 22 of 68 *KRAS* and *BRAF* wild-type mCRC patients did (14). Now, the use of anti-VEGF therapy combined with triplet chemotherapy in the first-line setting is recommended for mCRC patients (12). This history again supports our belief that biological principles revealed by basic cancer research can lead to real clinical practice.

¹Division of Epigenomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. ²Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Corresponding Author: Toshikazu Ushijima, National Cancer Center Research Institute, Division of Epigenomics, 5-1-1-Tsukiji, Chuo-kuTokyo, 104-0045 Japan. Phone: 81-3-3547-5240; Fax: 81-3-5565-1753; E-mail: tushijim@ncc.go.jp

doi: 10.1158/0008-5472.CAN-16-2867

©2016 American Association for Cancer Research.

From Intrinsic Resistance to Acquired Resistance

Acquisition of drug resistance during the course of treatment is a serious but almost inevitable issue. The identification of *KRAS* mutations as a cause for intrinsic resistance of colorectal cancers also contributed to the identification of a mechanism for the acquired resistance. Establishment and analysis of cetuximab-resistant colorectal cancer cell lines revealed that the resistant variants harbored *KRAS* point mutations or amplification, and the findings were confirmed in clinical specimens (15). Also, using circulating tumor DNA, the appearance of mutant *KRAS* was detected in 9 of 24 (38%) patients initially with wild-type *KRAS*, most of whom were initially sensitive to panitumumab but eventually developed the progressive disease (16).

In Vitro Treatment to Human Trials

Most importantly, Benvenuti and colleagues suggested a synergistic effect by the combination of cetuximab and a MAPK/ERK inhibitor. Afterward, Misale and colleagues conducted a systemic knockdown analysis of genes potentially involved in the resistance to anti-EGFR therapy and which were good candidates for therapy, namely *KRAS*, *NRAS*, *HRAS*, *BRAF*, *CRAF*, *MEK1/2*, *HER2*, *HER3*, *PIK3CA*, and *AKT1*, in colorectal cancer cell lines resistant to anti-EGFR therapy (17). Although the RAS-RAF-MEK-ERK pathway was activated in the resistant cell lines, the suppression of *MEK1/2* only marginally affected the growth of the resistant colorectal cancer cell lines. In contrast, concomitant inhibition of *MEK1/2* and *EGFR* suppressed growth of all the four resistant colorectal cancer cell lines examined.

Although the initial article by Benvenuti and colleagues employed a MAPK/ERK inhibitor along with cetuximab, the

concept of simultaneous inhibition of EGFR and the RAS-RAF-MEK-ERK pathway remained valid. Now, multiple clinical trials to combine EGFR inhibition and MEK inhibition, such as "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer" (NCT01750918), are being conducted. According to a presentation at ESMO in 2016, a combination of three drugs, a BRAF inhibitor, a MEK inhibitor, and an EGFR inhibitor, appears to be most effective against *BRAF*-mutated mCRCs.

Recent success of cancer immunotherapy initiated multiple clinical trials involving an immune checkpoint inhibitor and some of the BRAF/MEK/EGFR inhibitors (NCT01750918). Again, a scientific rationale that remains valid for decades is important.

Reward for Cancer Science and for Cancer Patients

As initially mentioned, the study by Benvenuti and colleagues was brief. However, the article contained important messages and was highly cited. It is rewarding for scientists that their articles are cited many times. At the same time, being cited means that the finding is likely to have had clinical impact, making the interest of scientists and patients shared. We have to note that although results from large clinical trials are often frequently cited and change clinical practice, their real original ideas are often translational research on a small scale. *Cancer Research* should continue to serve the scientific community and, as a result, cancer patients.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received October 19, 2016; accepted October 19, 2016; published online November 15, 2016.

References

- Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* 2007;67:2643-8.
- Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. *KRAS* mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006;66:3992-5.
- Benjamin LE. Commentary on "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer". *Cancer Res* 2016;76:4309-10.
- Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757-65.
- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type *KRAS* is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626-34.
- Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. *Cancer Discov* 2014;4:1269-80.
- Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. *Nat Rev Mol Cell Biol* 2008;9:517-31.
- De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, et al. Effects of *KRAS*, *BRAF*, *NRAS*, and *PIK3CA* mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010;11:753-62.
- Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clin Cancer Res* 2013;19:1902-12.
- Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013;369:1023-34.
- Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezínek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol* 2015;33:692-700.
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016;27:1386-422.
- Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. *Nat Rev Drug Discov* 2014;13:928-42.
- Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type *BRAF* is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008;26:5705-12.
- Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of *KRAS* mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012;486:532-6.
- Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012;486:537-40.
- Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. *Sci Transl Med* 2014;6:224ra26.